Meirovitz Amichay, Sheva Kim
The Legacy Heritage Oncology Center & Dr Larry Norton Institute, Soroka University Medical Center, Ben Gurion University of the Negev, Faculty of Medicine, Be'er Sheva, Israel.
The Legacy Heritage Oncology Center & Dr Larry Norton Institute, Soroka University Medical Center, Ben Gurion University of the Negev, Faculty of Medicine, Be'er Sheva, Israel.
Pract Radiat Oncol. 2025 Jul-Aug;15(4):e362-e370. doi: 10.1016/j.prro.2024.12.007. Epub 2025 Jan 6.
Continuous advancements in cancer management have resulted in increased long-term survival rates among cancer survivors, and in turn have exposed the full extent of radiation therapy-associated morbidities. Radiation-induced coronary heart disease (RICHD) is one of the leading causes of morbidity and mortality in cancer survivors, particularly in those having undergone mediastinal radiation. Although mediastinal radiation has been shown to substantially reduce both recurrence and mortality rates in multiple thoracic malignancies, the risk for the development of RICHD is of significant concern. Not only is the pathophysiology of RICHD yet to be fully elucidated, but therapeutic options are lacking.
Literature was reviewed with a focus on RICHD in Hodgkin's lymphoma, breast and patients with lung cancer, and the current modern radiotherapeutic techniques used to minimize radiation exposure of the heart.
Multiple approaches have been taken to minimize exposure of the heart to ionizing radiation in cancers that require mediastinal radiation, most notably Hodgkin's lymphoma, and breast and lung cancer. RICHD Protection strategies include optimized delineation protocols, utilization of the moderate deep inspiration breath hold (mDIBH), specialized mDIBH monitoring, continuous positive airway pressure and various other cardiac-sparing techniques. A combination of medical prevention and therapy with physical protective approaches may be vital in achieving significant cardio-protection.
Despite continuous advances and improvements in protective strategies, mainly by physically distancing the heart from radiation targets to minimize exposure and by sophisticated radiation dose planning, RICHD remains a significant challenge in cancer treatment rehabilitation and survivorship.
癌症治疗的不断进步使癌症幸存者的长期生存率提高,进而也使放疗相关的全部发病率得以显现。放射性冠心病(RICHD)是癌症幸存者发病和死亡的主要原因之一,尤其是在接受纵隔放疗的患者中。尽管纵隔放疗已被证明可显著降低多种胸部恶性肿瘤的复发率和死亡率,但RICHD的发生风险仍备受关注。不仅RICHD的病理生理学尚未完全阐明,而且缺乏治疗选择。
回顾了聚焦于霍奇金淋巴瘤、乳腺癌和肺癌患者中RICHD的文献,以及目前用于尽量减少心脏辐射暴露的现代放疗技术。
对于需要纵隔放疗的癌症,尤其是霍奇金淋巴瘤、乳腺癌和肺癌,已经采取了多种方法来尽量减少心脏对电离辐射的暴露。RICHD保护策略包括优化勾画方案、采用中等深度吸气屏气(mDIBH)、专门的mDIBH监测、持续气道正压通气以及各种其他心脏保护技术。医学预防和治疗与物理保护方法相结合可能对实现显著的心脏保护至关重要。
尽管保护策略不断进步和改进,主要是通过使心脏与辐射靶区保持物理距离以尽量减少暴露以及通过复杂的放射剂量规划,但RICHD在癌症治疗康复和生存方面仍然是一项重大挑战。